Paid Clinical Trials Aurora
Discover 1,026 paid clinical trials in Aurora, Colorado. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
LumateperoneMulticenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Sponsor:
Intra-Cellular Therapies, Inc.
Location:
Code:
NCT06372964
Conditions
Bipolar Depression
Eligibility Criteria
Sex: All
Age: 10 - 17
Healthy Volunteers: Not accepted
Interventions
Lumateperone
Placebo
LetrozoleLetrozole in Uterine Leiomyosarcoma
Sponsor:
GOG Foundation
Location:
Code:
NCT05649956
Conditions
Uterine Leiomyosarcoma
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Letrozole
DiamydA Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
Sponsor:
Diamyd Medical AB
Location:
Code:
NCT05018585
Conditions
Type 1 Diabetes Mellitus
Eligibility Criteria
Sex: All
Age: 12 - 28
Healthy Volunteers: Not accepted
Interventions
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®
Colecalciferol 2000 IU
Placebo
Werewolf Flow 50Werewolf Flow 50 During ACL Reconstruction
Sponsor:
Children's Hospital Colorado
Location:
Code:
NCT04998656
Conditions
Anterior Cruciate Ligament Injuries
Anterior Cruciate Ligament Rupture
Anterior Cruciate Ligament Tear
Arthrofibrosis of Knee
Eligibility Criteria
Sex: All
Age: 12 - 18
Healthy Volunteers: Not accepted
Interventions
Werewolf FLOW 50
Control
Observational StudyDysvascular Amputation Self-Management of Health
Sponsor:
University of Colorado, Denver
Location:
Code:
NCT04083456
Conditions
Amputation
Diabetes Mellitus
Peripheral Artery Disease
Eligibility Criteria
Sex: All
Age: 50 - 70+
Healthy Volunteers: Not accepted
Interventions
Walking Biobehavioral Intervention
Attention Control
Alisertib & Endocrine TherapyA Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Sponsor:
Puma Biotechnology, Inc.
Location:
Code:
NCT06369285
Conditions
Hormone Receptor Positive HER-2 Negative Breast Cancer
Metastatic Breast Cancer
Recurrent Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Alisertib
Endocrine therapy
IDE196 & CrizotinibIDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma
Sponsor:
IDEAYA Biosciences
Location:
Code:
NCT05987332
Conditions
Metastatic Uveal Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
IDE196
Crizotinib
Pembrolizumab
Ipilimumab
Nivolumab
RybelsusClinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)
Sponsor:
University of Colorado, Denver
Location:
Code:
NCT05892432
Conditions
Alcohol Use Disorder
Eligibility Criteria
Sex: All
Age: 21+
Healthy Volunteers: Not accepted
Interventions
Semaglutide 3 MG [Rybelsus]
Semaglutide 7 MG [Rybelsus]
Placebo
ABBV-383A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
Sponsor:
TeneoOne Inc.
Location:
Code:
NCT05650632
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
ABBV-383
AnifrolumabA 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
Sponsor:
AstraZeneca
Location:
Code:
NCT06015737
Conditions
Cutaneous Lupus Erythematosus
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
Anifrolumab
Placebo